Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
about
Melanoma: from melanocyte to genetic alterations and clinical optionsMutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cellsProliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.alphaB-crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells.Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survivalBRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Tumor suppressor p53 status does not determine the differentiation-associated G₁ cell cycle arrest induced in leukemia cells by 1,25-dihydroxyvitamin D₃ and antioxidants.Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.ANGPTL3 is a novel biomarker as it activates ERK/MAPK pathway in oral cancer.The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanomaMutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction BreakdownResponse to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.PLX4032: does it keep its promise for metastatic melanoma treatment?The role of mitogen- and stress-activated protein kinase pathways in melanoma.The future of targeted therapy approaches in melanoma.The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen.Cavin-2 in oral cancer: A potential predictor for tumor progression.Extracellular signal-regulated kinases 1/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41-5a cells.Persephin: A potential key component in human oral cancer progression through the RET receptor tyrosine kinase-mitogen-activated protein kinase signaling pathway.IGF-1 stimulated upregulation of cyclin D1 is mediated via STAT5 signaling pathway in neuronal cells.Human melanoma cells express FGFR/Src/Rho signaling that entails an adhesion-independent caveolin-1 membrane association.Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitroMutant B-RAF mediates resistance to anoikis via Bad and Bim.14-3-3β Depletion Drives a Senescence Program in Glioblastoma Cells Through the ERK/SKP2/p27 Pathway.RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.Microphthalmia-associated transcription factor/T-box factor-2 axis acts through Cyclin D1 to regulate melanocyte proliferation.Mechanisms in cardiac fibroblast growth: an obligate role for Skp2 and FOXO3a in ERK1/2 MAPK-dependent regulation of p27kip1.Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
P2860
Q21284811-35C84C02-30C7-46C6-8E63-46AA89869AE6Q28259285-A043B7B3-672E-41C9-A2EB-69840D0D670EQ33514138-0D4661AD-1403-4CCA-AD34-E8F37A6805F6Q33793960-A9BBB2AC-C0F1-4245-9414-32CE01FCE22BQ33840856-1DF93B03-1109-4817-8493-D210774EFA71Q33906044-99B119C6-17B8-4417-9E7F-BCC32A4D48F0Q33906093-D3C24313-0021-4AB3-B988-437ECBA68409Q34581838-0272391C-0AA3-4D6E-AE74-FAEC41377449Q35320304-F45CDD44-5EF8-40C3-98CD-C2C687DAC9C4Q35602157-879C8EB5-7596-4684-8389-5E6B0E4187BDQ35835097-5FBA9D7B-A3A9-4523-9D13-29DAF31707B3Q36418729-B77D2C73-CBBC-46E1-A8E8-2895682BE898Q36518235-F45A66A9-40AA-4E94-96BF-90F08B8389D6Q37542817-DBD8CFB8-F3DE-4AD4-A10B-6102A1B3452DQ37605787-50E88523-F06D-4F67-BBD4-FBF0F682650EQ37689575-EA4886E9-52D0-48F8-BF67-1EC03205E083Q37799845-050179DF-7D28-4F9A-9DF6-B96BEBC11DEEQ37931402-16BD8B3F-F169-46D8-A602-218E1BDBFF78Q38088812-66665A07-2904-498D-83C7-383250147C6FQ38481038-F8F056CD-C544-48F5-B1DC-6A7FCE61C4ADQ38783344-EB6D36B2-CB33-4667-BFF5-0FA9640BCD35Q38862698-EA9DA0C8-0785-4380-B7A2-68EBA2F67DF8Q38974584-AF5E4BE1-C090-4E99-9086-6915F41E3100Q39038712-E82D9590-3735-46AD-83B7-14057B46B514Q39179345-301158BC-F9EC-4CED-81DA-6002DFE83474Q39568935-86E569A6-01DD-401C-B083-3914BF443BBCQ39815389-B2128BD2-7B29-4BE9-BF5C-64B0BCA9EF10Q40031893-7127AA01-AEF3-41AB-BD53-6784D1F7F5EDQ40037013-5AFF2E31-D6EA-4F86-9839-0BDAE1F634D9Q41501598-2499A80F-14AC-4318-A8DD-87A2965FF839Q46774780-1915A1CF-446A-4597-B6DD-D264AAE84385Q48859144-0B3317CB-9086-4D64-9F92-5ED7CAED074DQ50068807-E77F4A83-6812-4F40-8766-9434ABA63A91Q50554165-C92C65D7-0611-45FB-86E2-E62D12797E89Q53071967-7450C5E3-9AA8-4E4C-B67B-337F5F9F0ED7Q53378605-51D42048-8977-40C1-898C-0473108331D3
P2860
Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling
description
im Februar 2005 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 2005
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2005
@uk
name
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@en
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@nl
type
label
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@en
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@nl
prefLabel
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@en
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@nl
P2093
P2860
P356
P1433
P1476
Adhesion control of cyclin D1 ...... through BRAF-MEK-ERK signaling
@en
P2093
Andrew E Aplin
Gazelle Aram
Kavita V Bhatt
Laurie S Spofford
Meghan McMullen
P2860
P2888
P304
P356
10.1038/SJ.ONC.1208544
P407
P577
2005-05-01T00:00:00Z